

# Accepted Manuscript

## Prognostic Role of Neutrophil-to-lymphocyte Ratio in Primary Non-muscle Invasive Bladder Cancer

David D'Andrea, Marco Moschini, Kilian Gust, Mohammad Abufaraj, Mehmet Özsoy, Romain Mathieu, Francesco Soria, Alberto Briganti, Morgan Rouprêt, Pierre I. Karakiewicz, Shahrokh F. Shariat

PII: S1558-7673(17)30069-1

DOI: [10.1016/j.clgc.2017.03.007](https://doi.org/10.1016/j.clgc.2017.03.007)

Reference: CLGC 808

To appear in: *Clinical Genitourinary Cancer*


Received Date: 30 December 2016

Revised Date: 17 March 2017

Accepted Date: 18 March 2017

Please cite this article as: D'Andrea D, Moschini M, Gust K, Abufaraj M, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, Shariat SF, Prognostic Role of Neutrophil-to-lymphocyte Ratio in Primary Non-muscle Invasive Bladder Cancer, *Clinical Genitourinary Cancer* (2017), doi: 10.1016/j.clgc.2017.03.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle invasive bladder cancer**

David D'Andrea<sup>a</sup> dd.dandrea@gmail.com  
 Marco Moschini<sup>ab</sup> marco.moschini87@gmail.com  
 Kilian Gust<sup>a</sup> kilian.gust@meduniwien.ac.at  
 Mohammad Abufaraj<sup>a</sup> dr.abufaraj@gmail.com  
 Mehmet Özsoy<sup>a</sup> mehmet.oezsoy@meduniwien.ac.at  
 Romain Mathieu<sup>c</sup> romainmath@yahoo.fr  
 Francesco Soria<sup>d</sup> soria.fra@gmail.com  
 Alberto Briganti<sup>b</sup> briganti.alberto@hsr.it  
 Morgan Rouprêt<sup>e</sup> morgan.roupret@aphp.fr  
 Pierre I. Karakiewicz<sup>f</sup> pierrekarakiewicz@gmail.com  
 Shahrokh F. Shariat<sup>afghi</sup> (corresponding author) sfshariat@gmail.com

**Affiliations**

<sup>a</sup> Department of Urology, Medical University of Vienna, Vienna, Austria  
<sup>b</sup> Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy  
<sup>c</sup> Department of Urology, Rennes University Hospital, Rennes, France  
<sup>d</sup> Department of Urology, University of Turin, Turin, Italy  
<sup>e</sup> Department of Urology, Pitié-Salpêtrière Hospital, APHP, University Paris VI, Paris, France  
<sup>f</sup> University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Quebec, Canada  
<sup>g</sup> Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY  
<sup>h</sup> University of Texas Southwestern, Department of Urology, Dallas, Texas  
<sup>i</sup> Karl Landsteiner University, Krems an der Donau, Austria

**Corresponding Author:** Shahrokh F. Shariat; Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria; Email sfshariat@gmail.com

**Abbreviations**

NLR = neutrophil-to-lymphocyte ratio  
 TURB = transurethral resection of the bladder  
 NMIBC = non-muscle invasive bladder cancer  
 MIBC = muscle invasive bladder cancer  
 RFS = recurrence-free survival  
 PFS = progression-free survival  
 EAU = European Association for Urology  
 BCG = Calmette-Guérin  
 UCB = urothelial carcinoma of the bladder  
 CIS = carcinoma in situ  
 RC = radical cystectomy  
 EORTC = European Organization for Research and Treatment of Cancer risk tables  
 IQR = Interquartile Ranges

Download English Version:

<https://daneshyari.com/en/article/5580979>

Download Persian Version:

<https://daneshyari.com/article/5580979>

[Daneshyari.com](https://daneshyari.com)